Taxane Coating Solid Form Conditioning for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for medical device coatings that can control the release rate of taxane therapeutic agents like paclitaxel without compromising durability, as existing coatings either release the agent too quickly or are not durable enough, and current packaging systems do not adequately protect these coatings from environmental factors.
Innovation Solution
A method of conditioning medical device coatings to alter the solid form of taxane therapeutic agents from amorphous to dihydrate forms, which slows down the release rate while maintaining durability, involves maintaining the coating at elevated humidity and temperature levels before implantation, allowing for a controlled release of the taxane therapeutic agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a medical device coating is made with high durability to withstand handling and implantation, then the coating durability is improved, but the release rate of the therapeutic agent becomes too slow
Solution Approach 1:
The patent applies parameter changes by controlling the relative humidity and temperature during packaging to transform the taxane solid form from amorphous to dihydrate, thereby adjusting the release rate parameter while preserving coating durability
Solution Approach 2:
The patent implements preliminary action by performing the solid form transformation during the packaging process before implantation, so that the coating is pre-conditioned with the desired release characteristics before being deployed in the patient
2Reliability
If the taxane therapeutic agent is stored in amorphous form for durability, then the coating durability is improved, but the agent releases too quickly after implantation
Solution Approach 1:
The patent changes the physical state parameter of the taxane from amorphous to dihydrate crystalline form through controlled humidity exposure during packaging, which fundamentally alters the release kinetics while preserving the durable coating structure
Solution Approach 2:
The patent uses the packaging environment as a temporary, disposable medium to induce the solid form transformation, after which the packaging is discarded and the device proceeds to implantation with the modified release characteristics
3Productivity
If the coating is conditioned at elevated humidity to slow release rate, then the release control is improved, but the coating may lose durability
Solution Approach 1:
The patent performs the humidity conditioning action during the packaging phase before implantation, so that the release rate is controlled without requiring prolonged high-humidity exposure that would compromise coating durability during device handling and storage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a controlled and sustained release of taxane therapeutic agents, reducing premature release and maintaining coating durability, thereby enhancing the therapeutic efficacy and longevity of the medical device.
Implementation Method 1
A taxane therapeutic agent can be formed in an amorphous form, or in at least two different crystalline polymorphs... This phenomenon is known as polymorphism, and the distinct species are known as polymorphs.
Implementation Method 2
Taxane therapeutic agent molecules can exist in solvated or non-solvated solid forms... The dihydrate taxane solid form typically has an opaque white color, while the amorphous dihydrate taxane solid form typically has a clear transparent appearance.
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
This disclosure relates to endolumenal medical devices coated with a taxane therapeutic agent in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous paclitaxel, dihydrate paclitaxel, or combinations thereof that provide durable coatings that release paclitaxel over a desired period of time, which can be on the order of hours, days or weeks. Preferred embodiments relate to medical device coatings of paclitaxel, or paclitaxel analogs or derivatives, having one or more polymorph solid forms that provide a prolonged release of paclitaxel within a body vessel without requiring a polymer carrier or barrier layer to achieve the desired rate of paclitaxel elution.